Want To Be Able To Tell When The Crypto Market Hits The Top? Analyst Sees This Pattern

Market analyst Frédéric Schneider — founder of algorithmic trading indicators development firm Material Indicators — suggested that there is one simple indicator for when the cryptocurrency market reached the top value of the current cycle.

Market analyst Frédéric Schneider — founder of algorithmic trading indicators development firm Material Indicators — suggested that there is one simple indicator for when the cryptocurrency market reached the top value of the current cycle.

What Happened: Schneider wrote in a Monday tweet, that the top phases of the cryptocurrency market’s cycles usually coincide with the daily number of altcoin trades being about 90% of the total number of daily crypto trades.

See Also: How to get free crypto

Altcoins are usually defined as cryptocurrencies that are not Bitcoin (CRYPTO: BTC) or a stablecoin, but in this instance also Ethereum (CRYPTO: ETH) and BNB (CRYPTO: BNB) were excluded. When confronted about why he excluded BNB, Schneider simply wrote that it only changes the result by about 1%, suggesting that it is not a notable change.

Schneider’s remarks follow prominent cryptocurrency analyst Benjamin Cowen sharing four lessons that he learned about how to survive a crypto bear market in mid-March.

BTC Price Action: As of press time, Bitcoin is trading at $40,088 after seeing its price fall by about 0.97% over the last 24 hours.

Total
0
Shares
Related Posts
Read More

European Medicines Agency’s Committee for Medicinal Products for Human Use Recommended Approval of Dupixent for Children Aged 6 to 11 Years with Severe Asthma with Type 2 Inflammation

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending to extend the approval of Dupixent® (dupilumab) in the European Union (EU) to include add-on maintenance treatment for children aged 6 to 11 years with severe asthma with type 2 inflammation characterized by raised blood eosinophils and/or raised fractional exhaled nitr

REGN

Read More

Analyzing Psychedelics & Traditional Pharma Interaction: New Clinical Trial Begins Dosing

Psychedelics biotech Small Pharma Inc. (OTCQB: DMTTF) confirmed that the first patient has been dosed in its Phase 1b study assessing the interaction between selective serotonin reuptake inhibitors (SSRIs) and proprietary lead DMT candidate SPL026 in patients with Major Depressive Disorder (MDD).

DMTTF